Ex vivo serum activity (killing rates) after gemifloxacin 320 mg versus trovafloxacin 200 mg single doses against ciprofloxacin-susceptible and -resistant Streptococcus pneumoniae

Int J Antimicrob Agents. 2002 Aug;20(2):144-6. doi: 10.1016/s0924-8579(02)00119-x.

Authors

A Calvo¹, M J Giménez, L Alou, M L Gómez-Lus, L Aguilar, J Prieto

Affiliation

¹ Department of Microbiology, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain.

PMID: 12297365
DOI: 10.1016/s0924-8579(02)00119-x

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase I
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Infective Agents / administration & dosage
Anti-Infective Agents / pharmacology*
Ciprofloxacin / pharmacology
Cross-Over Studies
Drug Resistance, Bacterial*
Fluoroquinolones*
Gemifloxacin
Humans
Male
Microbial Sensitivity Tests
Naphthyridines / administration & dosage
Naphthyridines / pharmacology*
Serum Bactericidal Test*
Streptococcus pneumoniae / drug effects*
Streptococcus pneumoniae / growth & development

Substances

Anti-Infective Agents
Fluoroquinolones
Naphthyridines
Ciprofloxacin
trovafloxacin
Gemifloxacin